27 February 2019 - - US-based clinical-stage biopharmaceutical company Imbrium Therapeutics L.P. and US-based biotech company TetraGenetics, Inc have forged a strategic research and development collaboration to utilise TetraGenetics' antibody discovery technology platform (TetraExpress) in the discovery and development of non-opioid biologic therapies for the treatment of chronic pain, the companies said.

Imbrium will leverage TetraGenetics' proprietary TetraExpress system to advance monoclonal antibodies that target specific ion channels that are scientifically important in the modulation of pain sensation.

The goal of this collaborative effort is to bring to market long-acting, non-opioid therapeutics that can treat a variety of pain conditions.

Imbrium is a clinical-stage biopharmaceutical company dedicated to advancing medical science through the development of important new pharmacologic and biologic therapeutics.

We are pursuing treatments for disorders of the central nervous system, oncology chemotherapeutics, and non-opioid approaches to the management of pain.

As an operating subsidiary of Purdue Pharma L.P., Imbrium strives to develop and bring to market new medicines that serve the unmet needs of patients, physicians, and health systems worldwide. 

We have built a robust and diversified pipeline of investigational drug candidates, and we actively collaborate with industry and academic partners to identify and advance future impactful medicines.

TetraGenetics is a pre-clinical drug discovery and development company.

It uses proprietary technology (TetraExpress) to discover large molecule drugs targeting ion channel and other membrane proteins associated with many human diseases.

The company's focus is the discovery and development of first-in-class biologics for autoimmune diseases and pain.

TetraGenetics establishes collaborative partnerships with major biotech companies for antibody drug discovery and pursues novel approaches to advance its proprietary drug pipeline.